Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$625.00K$625.00K−95.4% vs Q2 2021 Net Income-$22.32M-$22.32MN/M vs Q2 2021 EPS Diluted-$0.27-$0.27N/M vs Q2 2021 Operating Income-$22,423,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,673,000N/M Margins · derivedOperating margin-3587.7%−3538.7 pt vs Q2 2021
Net margin-3571.7%−3521.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end